Vaccine workshops: repository of materials
Washington DC: January 2013
Workshop on Business Modeling for Sustainable Influenza Vaccine Manufacturing
Washington, DC, January 14-16, 2013
Background materials
Presentations
Session 1 - Overview of Workshop Goals
-
Session 1 - Overview of Workshop Goals and Objectives
pdf, 251kb
Dr Marie-Paule Kieny, WHO; Dr Daniel Miller, HHS
Session 2 - Economics of Vaccines
-
Economic characteristics of vaccines and immunizations
pdf, 2.13Mb
Miloud Kaddar, WHO-IVB -
General overview of business models - Fundamental principles of sustainability
pdf, 570kb
Lisa Beth Ferstenberg, M.D. Director, Consulting Services Technical Resources International, Inc.
Session 3 - National and Global Parameters Affecting Vaccine Manufacture Sustainability
-
The complex system for vaccine manufacturing
pdf, 1.67Mb
Bruce Gellin, MD, MPH, Deputy Assistant Secretary for Health, Director, National Vaccine Program Office, Department of Health and Human Services -
Panel discussion: African Development Bank
pdf, 491kb
Dr Feng Zhao Manager, Health Division Human Development Department, African Development Bank -
Panel discussion: DCVMN
pdf, 317kb
Mahendra Suhardono, Production Director of Bio Farma, Indonesia; President of DCVMN -
Panel discussion: Ministry of Health, Colombia
pdf, 515kb
Claudia Patricia Vaca González, Pharmaceutical policy, Technical advisor, Ministry of Health, Colombia -
Panel discussion: GPO, Thailand
pdf, 583kb
Witit Artavatkun, M.D., Managing Director, Government Pharmaceutical Organization, Thailand
Session 4 - Attracting Investments and Generating Revenue - Theory, Practice and Existing Business Models
-
Valuing vaccines and influenza vaccine economics
pdf, 134kb
Peter Paradiso, Paradiso Biologics Consulting, LLC -
Categorization of developing country manufacturers, existing business models and impact on markets
pdf, 552kb
Miloud Kaddar, Senior Adviser, Health Economist, WHO, Geneva -
Case studies: Sanofi Pasteur
pdf, 838kb
Michael Watson, Sanofi Pasteur -
Case studies: Commonwealth Serum Laboratories
pdf, 1.03Mb
Bill Cracknell, Commonwealth Serum Laboratories -
Case study: Instituto Butantan
pdf, 825kb
Isaias Raw/Alexander Precioso, Instituto Butantan -
Case study: Bio Farma
pdf, 698kb
Mahendra Suhardono, Production Director of Bio Farma, Indonesia; President of DCVMN
Session 5 - The Impact of Technology and Method of Vaccine Production on Business Strategies and Opportunities
-
Influenza Vaccine Production – Impact of technology, scale and other vaccines on financial viability
pdf, 1.87Mb
Martin Friede, World Health Organization -
Influenza technology compatibility/leveragability with existing/other vaccine investments in a single facility
pdf, 659kb
Joshua Speidel, PhD,n Influenza Division, BARDA/ASPR -
Case study: Serum Institute of India
pdf, 694kb
F Marc LaForce, Serum Institute of India, Ltd -
Case study: Novartis
pdf, 603kb
Beverly Taylor, Novartis -
Case study: China National Biotec Group
pdf, 944kb
Qiyou Xiao, China National Biotec Group
Session 6 - Innovative Models: Meeting Investment Demands While Addressing National and Regional Public Health Needs
-
Vaccine development: reducing risks, responding to demand: which Innovative models?
pdf, 5.88Mb
Anthony D. So, MD, MPA, Program on Global Health and Technology Access, Duke University -
BARDA international and domestic capacity building activities
pdf, 798kb
Robert C. Huebner, Ph.D., Acting Director – Influenza Division, BARDA/ASPR -
PAHO Revolving Fund: how it works, specificities for seasonal influenza vaccine, experience during the 2009 pandemic influenza
pdf, 3.69Mb
Daniel Rodríguez (FCH/IM) Advisor, PAHO Revolving Fund -
Panel discussion: BIRMEX
pdf, 848kb
Ruth Velasquez Fernandez, Laboratorios de Biologicos y Reactivos de Mexico
Session 7 - National Regulatory Authority's Role in Product Commercialization, Licensing and Innovation of Influenza Vaccines
-
Panel discussion: ANVISA
pdf, 516kb
Marcelo Moreira, Coordinator of Biological Products Licensing, CPBIH/ANVISA -
Panel discussion: NEPAD/AMRH
pdf, 466kb
Margareth Ndomondo-Sigonda, Pharmaceutical Coordinator, African Union-NEPAD Agency
Session 8 - Role and Impact of Networks
-
Mission statement: DCVMN
pdf, 1.19Mb
Akira Homma, Developing Countries Vaccine Manufacturers’ Network -
Mission statement: AVMI
pdf, 816kb
Patrick Tippoo, African Vaccine Manufacturing Initiative
Session 9 - The Role of National and Regional Planning for Influenza Pandemic Preparedness
-
Influenza pandemic preparedness: mechanisms and factors to consider
pdf, 32kb
Michael Perdue, FluSolutions -
Panel discussion: US Department of Health and Human Services
pdf, 1.07Mb
Bruce Gellin, HHS
Session 10 - Opportunities in a Changing World - New Markets, New Procurers, Better Risk Management
-
New trends in the global vaccine market
pdf, 3.41Mb
Miloud Kaddar, Senior Adviser, Health Economist, WHO, IVB, Geneva
Session 11 - Holistic Approaches / Cross-Sectoral Policy
-
Unique and specific opportunities for developing country manufacturers
pdf, 437kb
Dr Marie-Paule Kieny, WHO